D-VCd improves hematologic CR rate to 59.5% compared to 19.2% in AL amyloidosis
Trial shows adding daratumumab improves outcomes for AL amyloidosis
This Phase 3 randomized controlled trial of 388 patients with newly diagnosed AL amyloidosis found that adding subcutaneous daratumumab to V…
Adding daratumumab to a standard drug combination helps patients with AL amyloidosis achieve faster and deeper responses in blood and organ …
Germline variants associated with chemotherapy-induced peripheral neuropathy show poor replication and limited clinical translation
Genetic Variations Linked to Chemotherapy Induced Nerve Damage
This systematic review of 72 studies assessed germline genetic variations related to vincristine, taxanes, platinum agents, and bortezomib. …
Specific genetic markers may be linked to nerve damage caused by chemotherapy, though these findings are not yet ready for use in clinical p…
Reduced-dose daratumumab and bortezomib may achieve partial renal remission in CyBorD-refractory PGNMID
Reduced Dose Daratumumab Shows Promise for Rare Kidney Disease
This case report describes a 73-year-old male with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) who ach…
A new case report shows a reduced dose of daratumumab may help manage severe kidney disease and heart failure in high-risk elderly patients.
Bortezomib, cyclophosphamide, and dexamethasone achieved remission in a patient with AL amyloidosis and POEMS syndrome
Treatment shows success for heart failure and rare blood diseases
This case report and literature review describes the treatment of an elderly male with concurrent AL amyloidosis and POEMS syndrome. The pat…
A new look at a complex case reveals how a specific drug combination helped an elderly man with multiple rare conditions.
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
FDA approves new drug Xpovio for certain blood cancers.
The FDA approved Xpovio (selinexor) for multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy, …
The FDA approved Xpovio (selinexor) for multiple myeloma and a type of lymphoma called DLBCL. It offers a new option for patients who have t…
Drug Response Profiling in pediatric ALL yields 68% objective responses and bridges to cellular therapies
Can a simple test find the right drug to save children with tough leukemia?
A prospective, multicenter Drug Response Profiling registry of 340 children with relapsed or refractory acute lymphoblastic leukemia in 17 E…
A simple test matching leukemia drugs to patient cells helped 68% of children respond to treatment and gave 28 of 42 patients a chance to su…
Observational study explores daratumumab resistance mechanisms in primary light-chain amyloidosis
Small study links daratumumab resistance to immune changes in light-chain amyloidosis
An observational cohort study of 30 patients with primary light-chain amyloidosis treated with daratumumab-bortezomib-dexamethasone found th…
Patients with weaker responses to amyloidosis treatment showed lower gene activity before therapy and increased immune stress during treatme…
SVRD yields 89.7% ORR, 79.3% EMD resolution in NDMM with EMD in phase 2 trial
Can a new drug combination help people with aggressive multiple myeloma? Early results show promise
In a phase 2 trial of 29 patients with newly diagnosed multiple myeloma and extramedullary disease (EMD), selinexor combined with VRD (SVRD)…
A new four-drug combination helped nearly 90% of patients with aggressive multiple myeloma shrink or eliminate cancer outside the bone marro…